Translate this page into:
Kidney Transplantation in Sickle Cell Disease Patients: Case Series and Experience from a Nigerian Kidney Transplant Center
-
Received: ,
Accepted: ,
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Sickle cell nephropathy is one of the long-term complications of sickle cell disease (SCD). About a quarter of SCD patients who survive up to 40 years of age will require some form of renal replacement therapy in their lifetime. Organ transplantation in SCD patients poses great challenges, particularly in lower middle income countries (LMIC) like Nigeria. This report highlights the management of three SCD patients who successfully underwent renal transplantation. The patients were aged 39, 47, and 58 years, respectively, with similarly previous history of multiple blood transfusions, recurrent vaso-occlusive crises, and had all progressed to end-stage renal disease. Preoperative exchange blood transfusion and plasmapheresis were offered in one and two of the patients, respectively. One of them required preoperative vaccination against encapsulated organisms due to autosplenectomy. Antithymocyte globulin was used as induction therapy in two of these patients while basiliximab was used in the third. All patients are alive with good renal function 18, 24, and 48 months post transplantation, respectively. In conclusion, kidney transplantation can be safely carried out on SCD patients with a satisfactory outcome.
Keywords
Kidney transplantation
Nigeria
sickle cell disease
Introduction
Sickle cell disease (SCD) is a common hemoglobinopathy characterized by sickling or insolubility of the hemoglobin tetramer following deoxygenation.[1] The renal complications are attributable to the effect of the relative acidic, hypoxic, and hypertonic medullary environment on the red blood cells in the vasa recta. This predisposes to repeated occlusion of the vasa recta with consequent local ischemia and infarction.[2] These changes manifest with hyposthenuria, papillary necrosis, glomerulosclerosis, and eventual renal failure.
Chronic kidney disease (CKD) is a major cause of morbidity and mortality in this group of patients with a global prevalence of 4%–18% which increases to as high as 20%–30% in SCD patients greater than 40 years old.[34] In Sub-Saharan Africa, SCD may present in adulthood with CKD requiring renal replacement therapy (RRT) and kidney transplantation (KT).[35] In Nigeria, where an estimated 2%–3% of its population is affected by SCD,[6] very few centers have the capacity for routine and regular hemodialysis and only a handful is offering kidney transplantation services. The poor access stems from lack of skilled manpower and facilities for KT, poor health insurance coverage, poverty, ignorance, and lack of a national constitution backing cadaveric kidney donation in Nigeria.[7] These circumstances put significant pressure on the limited pool of living donors and further limit spaces for KT in SCD patients who require highly specialized care for a successful outcome after transplantation.
From literature review, there has been no previous report of KT on SCD patients performed in Nigeria till date. We described three sickle cell disease patients who underwent KT exploring their clinical presentation, preoperative preparation, and outcomes following transplant surgery.
Case 1
A 39-year-old woman was referred to our facility for RRT. She was diagnosed with SCD at the age of 2 years with repeated episodes of vaso-occlusive crisis and hospital admissions [Baseline characteristics in Table 1]. She began to notice reduced urine output, facial and pedal edema, and hiccups for which she was diagnosed to have CKD five years prior and had progressed to ESRD. She also had avascular necrosis of the right head of femur. Investigations revealed that urinalysis showed proteinuria 3+, packed cell volume of 21%, and renal function was poor with urea of 168 mg/dl and creatinine of 11.3 mg/dl. The abdominal ultrasound showed bilateral shrunken kidneys and ascites. Chest X-ray showed marked cardiomegaly; echocardiography revealed left ventricular hypertrophy and left atrial dilatation. She was commenced on 3-weekly haemodialysis with intra-dialysis blood transfusions of 3 units of blood over 3 months and began preoperative evaluation for living related donor KT. The donor was her younger brother with whom she was ABO blood group compatible and had a human leukocyte antigen (HLA) match of 4/6. Details of histocompatibility, induction agents, and immunosuppression are noted on Table 2. Renal function normalized by the 3rd postoperative day. As at a clinic visit 1 year following surgery, the Urea-18 mg/dl and Cr-0.96 mg/dl. She is currently on tacrolimus, mycophenolate mofetil, prednisolone, calcium carbonate, vitamin C, folic acid, hydroxyurea, and pendopyl with acceptable Tac levels [Table 2].
| CASE 1 | CASE 2 | CASE 3 | |
|---|---|---|---|
| Age (Years) | 39 | 47 | 58 |
| Ethnicity | African | African | African |
| Sex | Female | Male | Male |
| BMI (Kg/m2) | 25.3 | 22.0 | 19.6 |
| Genotype | HbSS | HbSS | HbSS |
| Age at Diagnosis of HbSS (Years) | 2 | 4 | 5 |
| Time to CKD (Years) | 34 | 20 | 30 |
| Duration on Dialysis Prior to Transplant (Months) | 12 | 3 | 6 |
| Smoking | No | Yes | No |
| Hypertension | Yes | Yes | Yes |
| Average Number of Vaso-Occlusive Crisis | Several | Several | Several |
| Duration of Post Transplant Follow-Up (Months) | 48 | 24 | 18 |
| CASE 1 | CASE 2 | CASE 3 | |
|---|---|---|---|
| DSATiters/Management Protocol | Class I-200 Class II-120 |
Class I-2000 Class II-1215 |
Class I-658 Class II-250 |
| Human Leukocyte Antigen (HLA) Match | 4/6 | 3/6 | 2/6 |
| Additional Preoperative procedure | Nil | Plasma exchange + Intravenous Immunoglobulin (3 sessions) Vaccination against encapsulated organisms |
Exchange blood transfusion |
| Donor Profile | |||
| Age (Years) | 32 | 26 | 36 |
| Sex | Male | Male | Male |
| Hemoglobin Genotype | AA | AA | AA |
| Perioperative blood transfusion requirements (units) | 2 | 1 | 1 |
| Induction Agent (T Cell Depleting Antibody) | Basiliximab | Antithymocyte globulin (ATG) | Antithymocyte globulin (ATG) |
| Immunosuppressive Agents | Mycophenolatemofetil Tacrolimus |
Mycophenolatemofetil Tacrolimus |
Mycophenolatemofetil Tacrolimus |
| Corticosteroids | Methylprednisolone Prednisolone |
Methylprednisolone Prednisolone |
Methylprednisolone Prednisolone |
| Acute Rejection | NO | NO | NO |
| Sickle Cell Therapy | Hydroxyurea | Hydroxyurea | Hydroxyurea |
| Clinical Features (Post Transplant) | Renal function normalized | Renal function normalized | Lymphocele Renal function normalized |
Case 2
A 47-year-old male SCD patient presented with ESRD and desirous of KT. He was on twice weekly hemodialysis. He had battled several episodes of vaso-occlusive crises in childhood and had about 15 units of blood transfused in his lifetime. His last blood transfusion was 3 months prior to presentation in our clinic. His PCV ranged from 19% to 22% and his presenting renal function was Urea-112 mg/dl and Creatinine-10.1 mg/dl. His potential donor was his brother who was evaluated and found to be compatible with HLA match of 3/6. He had elevated donor specific antigen (DSA) titers of above 2000 for Class I antigens and a negative match for B & T cell lymphocytes.
Abdominal ultrasound revealed autosplenectomy and bilaterally shrunken kidneys. On account of the hyposplenic condition, he had vaccination against S. pneumoniae, N. meningitidis, H. influenza type b, and influenza virus 4 weeks before surgery. He required intra-operative transfusion of 1 unit of blood which was well tolerated. His renal function normalized by the 5th day of KT. He has been maintained on his immunosuppressants in the past 1 and half years with a normal renal function and Tac level-6.4ng/mL. On follow-up visits, he has been managed for two more episodes of vaso-occlusive crises.
Case 3
A 58-year-old man presented with severe anemia, CKD, and gout arthritis. He placed on maintenance hemodialysis three times weekly. He was also on his routine hematinics, hydroxyurea, antihypertensives and began preparation for KT. The donor was ABO blood group compatible and had a HLA 2/6 match. There was an unremarkable DSA titer and patient was negative for B & T cell lymphocytes. He has a session of exchange blood transfusion a night before surgery to further reduce the chances of perioperative crisis and had induction therapy using Antithymocyte Globulin (ATG). He had successful KT done with a smooth immediate postoperative recovery. He was noticed to have prolonged drainage of lymph via his abdominal wound drain and continued leakage of lymphatic fluid after discontinuation of the drain. He required ultrasound-guided drainage of the peri-allograft lymphocele 3 weeks post KT. And he is currently doing well on his immunosuppressants. His renal function has remained normal.
Discussion
Sickle cell disease is an uncommon cause of ESRD worldwide and is much more prevalent in sub-Saharan Africa.[8] These SCD patients require multiple blood transfusions in their lifetime, which could have contributed to the positive DSA titers, which necessitated plasma exchange and immunoglobulin administration for desensitization. As from this series, exchange blood transfusion and vaccination against encapsulated organisms (in auto-splenic patients) are important prerequisites to a successful KT in SCD patients with ESRD.
It is known that SCD patients present with ESRD at a relatively younger age than the general population. Considering that these young patients are likely to be good candidates for KT, only few SCD patients eventually had this procedure done.[9] Currently, it has been proven that the survival of SCD patients following KT has significantly improved with no significant overall survival difference between SCD patients and controls (ESRD patients from other causes).[19] Though it may be difficult to comment on the long-term survival of both our patients and allografts due to our short follow-up duration, we can only conclude that the short-term outcome has been encouraging with 100% survival at 2 years. This supports the finding from Ojo et al. and Gerardin et al. who found no significant difference in 2-year survival of SCD patients vs. controls, however a slightly lower survival in 5 and10 years.[910] In our study, living related donors with good HLA compatibilities played a major role in the successful outcome.
To have a successful outcome for the SCD kidney recipient, an intensive work-up for surgery must be followed. Donor selection is also a very important key factor. The peculiarities among sickle cell patients are that many close siblings or relatives might also be carrying the abnormal sickle cell gene. As part of our protocol, genotypes of all potential donors are requested and anyone with the abnormal sickle cell gene is excluded with AA donors favored. In our review though, two out of the three recipients got kidneys from their siblings. Many sickle patients are at high immunological risks as they would have had multiple blood transfusions necessitating the need for desensitization prior to transplant. In the same vein, for those with hyposplenism from autosplenetomy, vaccinations against S. pneumoniae, N. meningitidis, H. influenza type b, and influenza virus are strongly recommended at least 2 weeks before transplant surgery.[11]
Gradual correction of anemia by erythropoietin stimulation can be commenced months prior to surgery in order to limit the need for blood transfusions which could alter the immunologic milieu and hence increase the risk of acute rejection. For individuals who may require blood transfusion, it is advised to delay for a period of 3 months and repeat the cross-matches in order to rule out the presence of new antibodies or plasma exchange. Also, optimal hydration, adequate analgesia, antimalarials, antibiotic therapies, and thromboprophylaxis are all important for achieving good results. The liberal use of hydroxyurea in these patients pre and postoperatively has been shown to reduce incidents of crisis, acute chest syndrome, and mortality by up to 40%.[12] In our practice, hydroxyurea increases the fetal hemoglobin (HbF) concentration while reducing the HbS. This reduces the chances of vaso-occlusive episodes in the transplant period. A wide bore central line for hydration, arterial line for blood gas monitoring, and general anesthesia with good oxygenation gave our series a good outcome. Surgically, gentle dissection, meticulous hemostasis, and short warm and cold ischemic time enabled early graft function with normalization of renal function within 3 days. In the immediate postoperative period, liberal morphine-based patient-controlled analgesia was ensured to avoid pain-induced crisis.
In the post-transplant period, we ensure that all our sickle cell patients get oral hydroxyurea coupled with the immunosuppressants, antimalarial prophylaxis, co-trimoxazole for 6 months, prednisolone which we reduced to 5mg daily at 1 year, atorvastatin daily rabeprazole daily, valganciclovir for 6 months, tuberculosis prophylaxis for 3 months, antifungal prophylaxis for 3 months, liberal fluid intake, and regular clinic visits.
Septicemic complications are a common cause of perioperative mortality in SCD accounting for up to 23.3% of deaths,[10] hence the need for use of wound drains inserted intraoperatively and aggressive drainage of the peri-allograft collections like lymphocele to forestall progression into a peri-allograft abscesses. The hemoglobin concentrations of these patients improved remarkably following KT perhaps attributable to increased erythropoietin production from the renal allograft. There was no incidence of steroid-induced bony avascular necrosis in the follow-up period.
Conclusion
Kidney transplantation can safely be carried out in SCD patients in Nigeria. There is a need for appropriate donor and recipient selection, proper preoperative preparation with regards to the correction of chronic anemia, and adequate hemaodialysis and plasmapheresis in order to optimize these patients for surgery. The patients'short-term survival outcome in our practice is very encouraging.
Financial support and sponsorship
This study was funded by Zenith Medical and Kidney Center, Gudu Abuja Nigeria. There is no financial support from any association.
Conflicts of interest
There are no conflicts of interest.
Acknowledgement
We would like to acknowledge Dr. Thelma A.O who provided all the support for the execution and completion of this article.
References
- Improved survival among sickle cell kidney transplant recipients in the recent era. Nephrol Dial Transplant. 2013;28:1039-46.
- [Google Scholar]
- Renal replacement therapy in end-stage sickle cell nephropathy: presentation of two cases and literature review. Saudi J Kidney Dis Transpl. 2005;16:72-7.
- [Google Scholar]
- Renal function in patients over 40 with homozygous sicklecell disease. Br Med J. 1981;282:1181-3.
- [Google Scholar]
- Mortality in sickle cell disease: Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-44.
- [Google Scholar]
- Prevalence and patterns of sickle cell disease among children attending tertiary and non-tertiary health care institutions in a South Eastern State, Nigeria: A 10 year survey. J Res Med Dental Sci. 2016;4:183-9.
- [Google Scholar]
- Kidney transplantation in a developing economy: Challenges and initial report of three cases at Ile Ife. Cent Afr J Med. 2005;51:102-6.
- [Google Scholar]
- An appraisal of kidney dysfunction and its risk factors in patients with sickle cell disease. Nephron Clin Pract. 2011;118:225-31.
- [Google Scholar]
- Survival and specific outcome of sickle cell disease patients after renal transplantation. Br J Haematol. 2019;187:676-80.
- [Google Scholar]
- Renal transplantation in end-stage sickle cell nephropathy. Transplantation. 1999;67:291-5.
- [Google Scholar]
- Recommended vaccinations for asplenic and hyposplenic adult patients. HumVaccines Immunother. 2017;13:359-68.
- [Google Scholar]
- Effect of hydroxyureaon the frequency of painful crises in sickle cell anemia: Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332:1317-22.
- [Google Scholar]
